Penile cancer treatment costs in England

Abstract

BackgroundPenile cancer is a rare malignancy in Western countries, with an incidence rate of around 1 per 100,000. Due to its rarity, most treatment recommendations are based on small trials and case series reports. Furthermore, data on the resource implications are scarce. The objective of this study was to estimate the annual economic burden of treating penile cancer in England between 2006 and 2011 and the cost of treating a single case based on a modified version of the European Association of Urology penile cancer treatment guidelines.MethodsA retrospective (non-comparative) case series was performed using data extracted from Hospital Episode Statistics. Patient admission data for invasive penile cancer or carcinoma in situ of the penis was extracted by ICD-10 code and matched to data from the 2010/11 National Tariff to calculate the mean number of patients and associated annual cost. A mathematical model was simultaneously developed to estimate mean treatment costs per patient based on interventions and their associated outcomes, advised under a modified version of the European Association of Urologists Treatment Guidelines.ResultsApproximately 640 patients per year received some form of inpatient care between 2006 and 2011, amounting to an average of 1,292 spells of care; with an average of 48 patients being treated in an outpatient setting. Mean annual costs per invasive penile cancer inpatient and outpatient were £3,737 and £1,051 respectively, with total mean annual costs amounting to £2,442,020 (excluding high cost drugs). The mean cost per case, including follow-up, was estimated to be £7,421 to £8,063. Results were sensitive to the setting in which care was delivered.ConclusionsThe treatment of penile cancer consumes similar levels of resource to other urological cancers. This should be factored in to decisions concerning new treatment modalities as well as choices around resource allocation in specialist treatment centres and the value of preventative measures.Electronic supplementary materialThe online version of this article (doi:10.1186/s12889-015-2669-2) contains supplementary material, which is available to authorized users.

Exploring penile cancer survivors' motivations and experiences of attending a support group: eUROGEN study

“…Penile cancer is a rare and devastating malignancy, with an incidence of approximately 1 per 100 000 1 . Men frequently present between the ages of 50 and 70 years old 2 and there has been an increased incidence in England over the last 30 years 3 …”

Molecular carcinogenesis in equine penile cancer: A potential animal model for human penile cancer

“…These procedures are associated with high psychological morbidity and negatively impact the quality of life of affected patients [4]. In the UK, it is reported that there has been an increase in incidence of approximately 25% since 1985 [6,7]. The pathogenesis of human penile SCC (hPSCC) remains unclear; lack of circumcision, phimosis, cigarette-smoking and obesity have been widely discussed as potentially contributing to its development.…”

Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956–2015

“…The treatment of penile cancer is often mutilating, and may negatively impact on the quality of life and sexual functioning of patients . The treatment cost per case of penile cancer is substantial, and comparable to that of other urological cancers …”

“…11,12 The treatment cost per case of penile cancer is substantial, and comparable to that of other urological cancers. 13 Strong risk factors for penile cancer include phimosis and chronic inflammatory conditions. 14 The increased risk of penile cancer among men with phimosis is associated with lichen sclerosis or inadequate penile hygiene, smegma retention and thus infection.…”